FDA
-
-
-
-
-
-
-
Arcutis projects ZORYVE sales of $455-470 million for 2026
-
-
-
-
-
-
-
Arcutis publishes long-term ZORYVE safety data for seborrheic dermatitis
-
-
-
-
-
-
-
Arcutis presents new ZORYVE data on sleep quality and long-term control
-
-
-
-
-
-
-
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Arcutis Biotherapeutics Inc. (ARQT)
-
-
-
-
-
-
-
Arcutis Biotherapeutics (ARQT) appoints Latha Vairavan as CFO after Topper retirement
-
-
-
-
-
-
-
Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

